A clinical case of the effectiveness of chemo-targeted therapy in the first line of treatment for recurrent squamous cell carcinoma of the larynx

https://dx.doi.org/10.18565/pharmateca.2025.6.227-232

1) N.I. Pirogov Russian National Research Medical University, Moscow, Russia; 2) A.Tsyb Medical Radiology Research Center – Branch of the National Medical Research Radiological Center, Obninsk, Russia; 3) Moscow City Hospital named after S.S. Yudin, Moscow, Russia; 4) I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Background: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer, with laryngeal cancer accounting for only 0.6%. According to GLOBOCAN estimates (2022), approximately 890,000 new cases of HNSCC are registered worldwide each year, with mortality estimated at 450,000. In Russia in 2023, laryngeal cancer accounted for 2% of all malignant neoplasms among the male population. Despite the treatment, more than 50% of patients experience a relapse of the disease in the first 3 years. Modern methods of treating metastatic or recurrent HNSCC include both standard cytostatics and modern classes of antitumor drugs (targeted and immunotherapy).
Description of a clinical case: This article presents a clinical case of a long-term response to combined chemo-targeted (paclitaxel, carboplatin, cetuximab) therapy in a patient with recurrent squamous cell carcinoma of the larynx.
Conclusion: Combination chemo-targeted therapy (paclitaxel, carboplatin, cetuximab) as first-line treatment for recurrent/metastatic HNSCC demonstrates satisfactory tolerability with comparable oncological outcomes, especially in older patients and/or with significant comorbidities.

Keywords

About the Authors

Ekaterina A. Novgorodova, Student, Faculty of General Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; ORCID: https://orcid.org/0009-0004-3111-7663
Pavel V. Golubev, Cand. Sci. (Med.), Oncologist, Department of Antitumor Drug Therapy, A.Tsyb Medical Radiology Research Center – Branch of the National Medical Research Radiological Center, Obninsk, Russia; ORCID: https://orcid.org/0000-0003-3532-6476 (Corresponding author)
Evgenia S. Kuzmina, Cand. Sci. (Med.), Head of Chemotherapy Department No. 2, Oncology Center No. 1, Moscow City Hospital named after
S.S. Yudin, Moscow, Russia; ORCID: https://orcid.org/0009-0007-2856-5176
Dmitry S. Pikulin, Oncologist, Day Hospital for Antitumor Drug Therapy No. 2, Oncology Center No. 1, Moscow City Hospital named after S.S. Yudin, Moscow, Russia; ORCID: https://orcid.org/0009-0000-1037-9729
Vladislav M. Kuzmin, Student, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ORCID: https://orcid.org/0009-0000-9658-3586
V.N. Galkin, Dr. Sci. (Med.), Professor, Chief Physician, Moscow City Hospital named after S.S. Yudin, Moscow, Russia; ORCID: https://orcid.org/0000-0002-6619-6179

Similar Articles